Galápagos Clinical Trials

Trial result page for

[Idiopathic Pulmonary Fibrosis]

A clinical study to test how effective and safe GLPG1690 is for subjects with Idiopathic Pulmonary Fibrosis (IPF) when used together with standard of care (ISABELA1)

Recruiting

This trial is run by Gilead, a Galapagos partner company. Gilead are responsible for the information provided on this clinical trial. You can find more information on Gilead trials and **clinical trials policy**. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nunc sed hendrerit neque. Etiam hendrerit metus leo, vitae tincidunt, ipsum sed quantum. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nunc sed hendrerit neque.

Trial purpose

The main purpose of this study is to see how GLPG1690 works together with your current standard treatment on your lung function and IPF disease in general. The study will also investigate how well GLPG1690 is tolerated (for example if you get any side effects while on study drug).

Gender

Male and female

Age range

40 years and older

Phase

Phase 3

Study dates

Nov 2018 - Dec 2020

Eligibility criteria

Inclusion criteria +

Exclusion criteria −

- History of malignancy within the past 5 years (except for carcinoma in situ of the uterine cervix, basal cell carcinoma of the skin that has been treated with no evidence of recurrence, prostate cancer that has been medically managed through active surveillance or watchful waiting, squamous cell carcinoma of the skin if fully resected, and Ductal Carcinoma In Situ).
- Clinically significant abnormalities detected on ECG of either rhythm or

conduction, a QT interval corrected for heart rate using Fridericia's formula (QTcF) >450 ms, or a known long QT syndrome. Patients with implantable cardiovascular devices (e.g. pacemaker) affecting the QT

Where to participate



Country	**United States**
Location	Rhode Island Hospital, Providence, Rhode Island, United States, 02903
Trial status	**Not yet recruiting**

Country	**United Kingdom**
Location	Birmingham Heartlands Hospital, Birmingham, United Kingdom, B9 5SS
Trial status	**Completed**

Country	**United States**
Location	Rhode Island Hospital, Providence, Rhode Island, United States, 02903
Trial status	**Not yet recruiting**

What to do next if you're interested in this trial

Protocol number:
GLPG1690-CL-303

Clinicaltrials.gov identifier:
NCT03711162

EudraCT Number:
2018-001405-87

Product/drug type:
GLPG1690

Official title: Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nunc sed hendrerit neque. Etiam hendrerit metus leo, vitae tincidunt lectus sollicitudin ut. Aliquam cursus, ex et imperdiet dignissim, enim ipsum blandit nulla, non sodales nunc leo non lacus. Nunc nec eros fringilla, venenatis mauris ut, tincidunt nunc.

Download this page

Email this page

Back to search results